Mara Aspinall Named President of Genzyme Genetics

Apr 05, 2001, 01:00 ET from Genzyme General

    CAMBRIDGE, Mass., April 5 /PRNewswire/ -- Genzyme General, a division of
 Genzyme Corp., announced today that Mara Aspinall has been named president of
 Genzyme Genetics.  In this role, Aspinall will direct the growth and
 development of Genzyme Genetics, a world leader in diagnostic testing services
 focused in a variety of areas including prenatal care and cancer.
     Aspinall will continue to serve as president of Genzyme Pharmaceuticals, a
 position she held while also president of the emerging technologies group.
 She joined Genzyme in 1997 as vice president of corporate development.
     "This is an exciting and important time for genetic testing and we are
 positioned as a market leader, continuing to bring new technology and services
 to customers," said Jan van Heek, executive vice president of Genzyme Corp.,
 responsible for therapeutics, genetics, and pharmaceuticals.  "Mara has done
 an excellent job increasing the revenue of our pharmaceuticals business,
 shifting to higher margin products and upgrading our manufacturing facilities.
 I am confident she will continue to build on the successful performance of
 Genzyme Genetics."
     Genzyme Genetics, a business unit made up of over 500 employees, has
 genetic testing facilities in several locations throughout the world including
 Massachusetts, New Mexico, California, New York, and Florida.  With a staff of
 60 genetic counselors and medical geneticists, Genzyme Genetics provides
 genetic counseling at over 200 nationwide locations and also offers testing
 services in Japan and Germany.
     Prior to joining Genzyme, Aspinall was a director at the law firm Hale and
 Dorr LLP, and a senior consultant with Bain & Company specializing in
 strategic planning, business development, and marketing.  She holds an MBA
 from Harvard Business School and an undergraduate degree from Tufts
 University.
     Genzyme General develops and markets therapeutic products and diagnostic
 products and services.  Genzyme General has four therapeutic products on the
 market and a strong pipeline of products in development focused on the
 treatment of genetic disorders and other chronic debilitating diseases with
 well-defined patient populations.  Genzyme General is a division of the
 biotechnology company Genzyme Corporation.
 
     This press release contains forward-looking statements based on
 management's current expectations, including without limitation statements
 concerning the performance of Genzyme Genetics.  Actual results may materially
 differ due to numerous factors, including without limitation: the actual
 results of operations, including research and development activities and sales
 and marketing efforts; the competitive environment for genetic testing
 services; the impact of the anticipated increase in oversight of genetic
 testing by the FDA and Centers for Disease Control; and the risks and
 uncertainties described in reports filed by Genzyme Corporation with the
 Securities and Exchange Commission under the Securities Exchange Act of 1934,
 as amended, including without limitation Exhibit 99.2 to Genzyme's 2000 Annual
 Report on Form 10-K, as amended.  Genzyme General Division common stock is a
 series of common stock of Genzyme Corporation.  Therefore, holders of Genzyme
 General Division common stock are subject to all of the risks and
 uncertainties described in the aforementioned reports.
 
      Genzyme's releases are on the World Wide Web at http://www.genzyme.com.
 They are also available from Genzyme's fax-on-demand service at 1-800-436-1443
 within the United States or 1-201-521-1080 outside the United States.
 
 

SOURCE Genzyme General
    CAMBRIDGE, Mass., April 5 /PRNewswire/ -- Genzyme General, a division of
 Genzyme Corp., announced today that Mara Aspinall has been named president of
 Genzyme Genetics.  In this role, Aspinall will direct the growth and
 development of Genzyme Genetics, a world leader in diagnostic testing services
 focused in a variety of areas including prenatal care and cancer.
     Aspinall will continue to serve as president of Genzyme Pharmaceuticals, a
 position she held while also president of the emerging technologies group.
 She joined Genzyme in 1997 as vice president of corporate development.
     "This is an exciting and important time for genetic testing and we are
 positioned as a market leader, continuing to bring new technology and services
 to customers," said Jan van Heek, executive vice president of Genzyme Corp.,
 responsible for therapeutics, genetics, and pharmaceuticals.  "Mara has done
 an excellent job increasing the revenue of our pharmaceuticals business,
 shifting to higher margin products and upgrading our manufacturing facilities.
 I am confident she will continue to build on the successful performance of
 Genzyme Genetics."
     Genzyme Genetics, a business unit made up of over 500 employees, has
 genetic testing facilities in several locations throughout the world including
 Massachusetts, New Mexico, California, New York, and Florida.  With a staff of
 60 genetic counselors and medical geneticists, Genzyme Genetics provides
 genetic counseling at over 200 nationwide locations and also offers testing
 services in Japan and Germany.
     Prior to joining Genzyme, Aspinall was a director at the law firm Hale and
 Dorr LLP, and a senior consultant with Bain & Company specializing in
 strategic planning, business development, and marketing.  She holds an MBA
 from Harvard Business School and an undergraduate degree from Tufts
 University.
     Genzyme General develops and markets therapeutic products and diagnostic
 products and services.  Genzyme General has four therapeutic products on the
 market and a strong pipeline of products in development focused on the
 treatment of genetic disorders and other chronic debilitating diseases with
 well-defined patient populations.  Genzyme General is a division of the
 biotechnology company Genzyme Corporation.
 
     This press release contains forward-looking statements based on
 management's current expectations, including without limitation statements
 concerning the performance of Genzyme Genetics.  Actual results may materially
 differ due to numerous factors, including without limitation: the actual
 results of operations, including research and development activities and sales
 and marketing efforts; the competitive environment for genetic testing
 services; the impact of the anticipated increase in oversight of genetic
 testing by the FDA and Centers for Disease Control; and the risks and
 uncertainties described in reports filed by Genzyme Corporation with the
 Securities and Exchange Commission under the Securities Exchange Act of 1934,
 as amended, including without limitation Exhibit 99.2 to Genzyme's 2000 Annual
 Report on Form 10-K, as amended.  Genzyme General Division common stock is a
 series of common stock of Genzyme Corporation.  Therefore, holders of Genzyme
 General Division common stock are subject to all of the risks and
 uncertainties described in the aforementioned reports.
 
      Genzyme's releases are on the World Wide Web at http://www.genzyme.com.
 They are also available from Genzyme's fax-on-demand service at 1-800-436-1443
 within the United States or 1-201-521-1080 outside the United States.
 
 SOURCE  Genzyme General